NSAIDs for analgesia in the era of COVID-19

Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzberg, Daniel L, Sukumaran, Harry P, Viscusi, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476293/
https://www.ncbi.nlm.nih.gov/pubmed/32499385
http://dx.doi.org/10.1136/rapm-2020-101584
_version_ 1783579678359945216
author Herzberg, Daniel L
Sukumaran, Harry P
Viscusi, Eugene
author_facet Herzberg, Daniel L
Sukumaran, Harry P
Viscusi, Eugene
author_sort Herzberg, Daniel L
collection PubMed
description Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one’s likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.
format Online
Article
Text
id pubmed-7476293
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74762932020-09-30 NSAIDs for analgesia in the era of COVID-19 Herzberg, Daniel L Sukumaran, Harry P Viscusi, Eugene Reg Anesth Pain Med Special Article Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one’s likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need. BMJ Publishing Group 2020-09 2020-06-03 /pmc/articles/PMC7476293/ /pubmed/32499385 http://dx.doi.org/10.1136/rapm-2020-101584 Text en © American Society of Regional Anesthesia & Pain Medicine 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
spellingShingle Special Article
Herzberg, Daniel L
Sukumaran, Harry P
Viscusi, Eugene
NSAIDs for analgesia in the era of COVID-19
title NSAIDs for analgesia in the era of COVID-19
title_full NSAIDs for analgesia in the era of COVID-19
title_fullStr NSAIDs for analgesia in the era of COVID-19
title_full_unstemmed NSAIDs for analgesia in the era of COVID-19
title_short NSAIDs for analgesia in the era of COVID-19
title_sort nsaids for analgesia in the era of covid-19
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476293/
https://www.ncbi.nlm.nih.gov/pubmed/32499385
http://dx.doi.org/10.1136/rapm-2020-101584
work_keys_str_mv AT herzbergdaniell nsaidsforanalgesiaintheeraofcovid19
AT sukumaranharryp nsaidsforanalgesiaintheeraofcovid19
AT viscusieugene nsaidsforanalgesiaintheeraofcovid19

Ejemplares similares